[Brown urine : Myoglobin-induced renal failure after concomitant administration of simvastatin and amiodarone]

Anaesthesist. 2016 May;65(5):366-8. doi: 10.1007/s00101-016-0171-6. Epub 2016 May 3.
[Article in German]

Abstract

Rhabdomyolysis is a rare but well-known complication of statin therapy. The risk is considerably increased when concomitant drugs are administered that inhibit metabolism and breakdown via the cytochrome CYP3A4. We report a case of myoglobin-induced acute renal failure secondary to the concomitant use of simvastatin and amiodarone. The risk of rhabdomyolysis is mainly determined by the statin dose; in the case of the concomitant use of CYP3A4 inhibitors, a maximal daily dose of 20 mg is recommended to avoid harmful drug interactions.

Keywords: Acute renal failure; Amiodaron; Myoglobinuria; Rhabdomyolyse.

Publication types

  • Case Reports

MeSH terms

  • Acute Kidney Injury / chemically induced*
  • Acute Kidney Injury / urine*
  • Aged
  • Amiodarone / adverse effects*
  • Drug Interactions
  • Enzyme Inhibitors / adverse effects*
  • Humans
  • Hydroxymethylglutaryl-CoA Reductase Inhibitors / adverse effects*
  • Male
  • Myoglobinuria / urine*
  • Renal Replacement Therapy
  • Rhabdomyolysis / chemically induced
  • Shock, Septic / complications
  • Shock, Septic / drug therapy
  • Simvastatin / adverse effects*

Substances

  • Enzyme Inhibitors
  • Hydroxymethylglutaryl-CoA Reductase Inhibitors
  • Simvastatin
  • Amiodarone